Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE008 (KOR) (Dr. Kim)
· consented 2022-11-15
Adverse events
4
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
severe
assessed
2026-08-18
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-31 (study day 240); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-12-30 (study day 392); relationship: N
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-12-06 (study day 734); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2025-01-12 (study day 771); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.